KRAS-dependent cancer cells promote survival by producing exosomes enriched in Survivin

The Frequency of Ras Mutations in Cancer

(2020) Ian A. Prior et al.   CANCER RESEARCH

Pancreatic cancer

(2020) Jonathan D Mizrahi et al.   LANCET

RAS-targeted therapies: is the undruggable drugged?

(2020) Amanda R. Moore et al.   NATURE REVIEWS DRUG DISCOVERY

Rab13 regulates sEV secretion in mutant KRAS colorectal cancer cells

(2020) Scott A. Hinger et al.   Scientific Reports

Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers

(2019) Conan G. Kinsey et al.   NATURE MEDICINE

Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer

(2019) Kirsten L. Bryant et al.   NATURE MEDICINE

Reassessment of Exosome Composition

(2019) Dennis K. Jeppesen et al.   CELL

Loss of Sirtuin 1 Alters the Secretome of Breast Cancer Cells by Impairing Lysosomal Integrity

(2019) Arash Latifkar et al.   DEVELOPMENTAL CELL

Survivin at a glance

(2019) Sally P. Wheatley et al.   JOURNAL OF CELL SCIENCE

RAS in pancreatic cancer

(2019) Simone Lanfredini et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

(2019) Jude Canon et al.   NATURE

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

(2019) Jill Hallin et al.   Cancer Discovery

Mechanism of recipient cell-dependent differences in exosome uptake

(2018) Sayo Horibe et al.   BMC CANCER

Exosomes released from pancreatic cancer cells enhance angiogenic activities via dynamin-dependent endocytosis in endothelial cells in vitro

(2018) Mitsuru Chiba et al.   Scientific Reports

Drugging RAS: Know the enemy

(2017) Bjoern Papke et al.   SCIENCE

Metabolic Interactions in the Tumor Microenvironment

(2017) Costas A. Lyssiotis et al.   TRENDS IN CELL BIOLOGY

KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer

(2017) Andrew M. Waters et al.   Cold Spring Harbor Perspectives in Medicine

Microvesicle Cargo and Function Changes upon Induction of Cellular Transformation

(2016) Bridget T. Kreger et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism

(2016) P. Lito et al.   SCIENCE

The Enrichment of Survivin in Exosomes from Breast Cancer Cells Treated with Paclitaxel Promotes Cell Survival and Chemoresistance

(2016) Bridget Kreger et al.   Cancers

Glypican-1 identifies cancer exosomes and detects early pancreatic cancer

(2015) Sonia A. Melo et al.   NATURE

Survivin expression and serum levels in pancreatic cancer

(2015) He Dong et al.   World Journal of Surgical Oncology

Survivin and YM155: How faithful is the liaison?

(2014) Anke Rauch et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Dragging Ras Back in the Ring

(2014) Andrew G. Stephen et al.   CANCER CELL

KRAS: feeding pancreatic cancer proliferation

(2014) Kirsten L. Bryant et al.   TRENDS IN BIOCHEMICAL SCIENCES

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

(2013) Jonathan M. Ostrem et al.   NATURE

Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism

(2012) Haoqiang Ying et al.   CELL

Tumor-Derived Microvesicles Induce Proangiogenic Phenotype in Endothelial Cells via Endocytosis

(2012) Taisuke Kawamoto et al.   PLoS One

A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer

(2011) A. W. Tolcher et al.   ANNALS OF ONCOLOGY

Serum Biomarker Panels for the Detection of Pancreatic Cancer

(2011) R. E. Brand et al.   CLINICAL CANCER RESEARCH

KRASmutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: Implication for combinatorial approach

(2010) Young-Kwang Yoon et al.   MOLECULAR CARCINOGENESIS

Phase I Study of YM155, a Novel Survivin Suppressant, in Patients with Advanced Solid Tumors

(2009) T. Satoh et al.   CLINICAL CANCER RESEARCH

A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma

(2009) Karl D. Lewis et al.   INVESTIGATIONAL NEW DRUGS

Multicenter Phase II Trial of YM155, a Small-Molecule Suppressor of Survivin, in Patients With Advanced, Refractory, Non–Small-Cell Lung Cancer

(2009) Giuseppe Giaccone et al.   JOURNAL OF CLINICAL ONCOLOGY

Ceramide Triggers Budding of Exosome Vesicles into Multivesicular Endosomes

(2008) K. Trajkovic et al.   SCIENCE